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Background: The incidence of clinically apparent stroke in transcatheter aortic valve implantation (TAVI) exceeds
that of any other procedure performed by interventional cardiologists and, in the index admission, occurs more
than twice as frequently with TAVI than with surgical aortic valve replacement (SAVR). However, this represents only
a small component of the vast burden of neurological injury that occurs during TAVI, with recent evidence
suggesting that many strokes are clinically silent or only subtly apparent. Additionally, insult may manifest as slight
neurocognitive dysfunction rather than overt neurological deficits. Characterisation of the incidence and underlying
aetiology of these neurological events may lead to identification of currently unrecognised neuroprotective
strategies.
Methods: The Silent and Apparent Neurological Injury in TAVI (SANITY) Study is a prospective, multicentre,
observational study comparing the incidence of neurological injury after TAVI versus SAVR. It introduces an
intensive, standardised, formal neurologic and neurocognitive disease assessment for all aortic valve recipients,
regardless of intervention (SAVR, TAVI), valve-type (bioprosthetic, Edwards SAPIEN-XT) or access route (sternotomy,
transfemoral, transapical or transaortic). Comprehensive monitoring of neurological insult will also be recorded
to more fully define and compare the neurological burden of the procedures and identify targets for harm
minimisation strategies.
Discussion: The SANITY study undertakes the most rigorous assessment of neurological injury reported in the
literature to date. It attempts to accurately characterise the insult and sustained injury associated with both TAVI
and SAVR in an attempt to advance understanding of this complication and associations thus allowing for
improved patient selection and procedural modification.
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Emerging data now supports transcatheter aortic valve
implantation (TAVI) as an acceptable strategy in the
management of severe aortic stenosis (AS) amongst pa-
tients deemed ineligible or too high-risk for SAVR. Des-
pite the technique’s success, the risk of neurological
insult and injury associated with TAVI has raised con-
cerns [1]. This may take the form of either cerebrovascu-
lar events (CVEs) – including major/disabling stroke,
minor/non-disabling stroke, transient ischemic attacks
(TIAs) or silent brain infarcts; or neurocognitive dys-
function - especially post-operative cognitive dysfunction
(POCD) and post-operative delirium (POD). Such events
may be overt, subtle, or clinically silent (Figure 1). While
overt stroke rates have been reported in most safety and
efficacy studies/registries, subtle and silent neurological
events have been unreliably detected due to limitations
of assessment tools and prevailing clinical approaches.
Additionally, although emboli are thought to be the
major cause especially of early neurological injury the
underlying insults behind both types of injury remain
poorly characterised.
Clinically apparent cerebrovascular events
Strokes/TIAs (as defined in Table 1) are more common
post-TAVI than after alternative management strategies,
with the highest reported incidence for any cardiac
procedure [2]. Thirty-day stroke rates of 3.3%, 2.4%
and 1–2% have been reported for populations undergo-
ing TAVI, isolated SAVR, and balloon valvuloplasty,
respectively [3-5]. For all three interventions, this risk
is highest within the first 24 hours, suggesting an early
hazard phase immediately post-procedure [6,7]. This earlyClinically Apparent Clinically
but oft
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Figure 1 Schema of neurological injury in TAVI.hazard phase is considered ‘procedurally-related’ and
represents the period during which TAVI recipients are
at increased risk. Improved understanding of events
during this period therefore promises the greatest poten-
tial for optimisation of TAVI and as such is the focus of
the SANITY Study.
Silent brain infarction
In neuroimaging studies, clinically apparent strokes ac-
count for only a minority of CVEs. Diffusion-weighted
magnetic resonance imaging (DWI) studies have re-
vealed the average incidence of new ischemic lesions as
75% post-TAVI, and as high as 93% [8,9]. Compara-
tively, only 40–50% are evident on DWI studies follow-
ing SAVR, and 22% following retrograde catheterisation
of the aortic valve in AS [8,10]. Understanding of these
clinically silent CVEs is more limited than for clinically
apparent strokes, with only a few published MRI-centred
studies investigating their occurrence post-TAVI, amount-
ing to fewer than 200 patients. The clinical relevance
of this burden of infarct remains unknown, though has
been suggested to correlate with increased risk of post-
operative cognitive dysfunction (POCD) or post-operative
delirium (POD) [11,12]. Furthermore, DWI has recently
been recommended as a useful surrogate endpoint for
quantifying neurological injury due to the relative rarity of
clinically apparent neurological injury [13].
Neurocognitive impairment
Investigation into neurological injury post-TAVI has al-
most exclusively focused on CVEs, with little attention
given to neurocognitive/neuropsychological disturbances.
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Table 1 Classification and definitions of neurological injury/impairment
A. Cerebrovascular events [17]
Silent Cerebral infarcts that are observed on magnetic resonance imaging (MRI) scans in the absence of any
corresponding, clinically apparent cerebrovascular ischaemic event.
Clinically apparent Acute episode of a focal or global neurological deficit with at least one of the following: change in the level of
consciousness, hemiplegia, hemiparesis, numbness, or sensory loss affecting one side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke.
a. Stroke Duration of a focal or global neurological deficit≥ 24 hours; OR <24 hours if available neuroimaging documents
a new hemorrhage or infarct; OR the neurological deficit results in death.
Aetiology i. Ischemic: an acute episode of focal cerebral, spinal or retinal dysfunction caused by infarction of the central
nervous system tissue.
ii. Haemorrhagic: an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal,
intraventricular, or subarachnoid haemorrhage.
iii. Undetermined: insufficient information to allow categorization as ischemic or haemorrhagic.
Severity i. Disabling stroke (Major): an mRS of 2 or more at 90 days and an increase in at least one mRS category from
an individuals pre-stroke baseline.
ii. Non-disabling stroke (Minor): an mRS score of <2 at 90 days or one that does not result in an increase in at
least one mRS category from an individual’s pre-stroke baseline.
b. TIA:
b. TIA Duration of a focal or global neurological deficit <24 hours, any available neuroimaging does not demonstrate a
new haemorrhage or infarct.
Qualifiers • Exclusion of non-stroke causes for clinical presentation
o e.g. brain tumour, trauma, infection, hypoglycaemia, peripheral lesion, pharmacological influences etc.
• Determined by or in conjunction with the designated internal medicine specialist or neurologist.
• Diagnosis confirmed by at least one of the following:
• Neuroimaging procedure (CT scan or MRI brain) and/or
• Neurologist or neurosurgical specialist.
B. Neurocognitive impairment
a. POCD Definition: Deterioration of intellectual function presenting as impaired memory or concentration presenting
with temporal association to surgery.
b. POD Definition: An acute disturbance of consciousness and a change in cognition with tendency to fluctuate during
the course of the day and occurring in patients without some other identifiable aetiology and following normal
emergence from anaesthesia.
Qualifiers
• In conjunction with CAM and MoCA assessment tools
Adapted from Kappetein et al. [17] with permission of the publisher.
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clinical detection. Two entities of particular interest are
POD and POCD, which are outlined in Table 1. Though
clinical experience suggests that these are common en-
tities post-cardiovascular intervention, studies geared
towards their detection following TAVI are sparse.
Neurological insult
The underlying neurological insult resulting in injury is
thought to be primarily an embolic phenomenon [2].
Transcranial Doppler (TCD) studies have demonstrated
microemboli at all stages of the TAVI procedure, with
cumulative embolic loads exceeding 500 high-intensity
signals (HITS, a validated surrogate of emboli) reported,
especially during stages of aortic valve manipulation/
TAVI deployment. A recent study employing embolicprotection devices has demonstrated that a large number
of such emboli are particulate in nature and include
acute and chronic thrombus, atheromatous, calcific and
valve/vascular tissue [14].
In addition to emboli, cerebral hypoperfusion is also
likely a significant contributory factor, both in precipita-
ting ischemia and magnifying the effects of microemboli
[15]. Indeed, a pilot study employing cerebral oximetry
has confirmed statistically significant reductions in cere-
bral oxygen saturations most notably during periods of
rapid ventricular pacing during valvuloplasty and valve
deployment [16].
Generally, the data used to quantify and characterise
the aetiology of the neurological insult is based on a lim-
ited number of small studies. Furthermore, no studies
to date have correlated neurological insult detected by
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logical injury within the same cohort of patients.
Area of need
Clearly, current understanding of the nature and character
of both the neurologic injury and the underlying insult as-
sociated with TAVI is incomplete. The paucity of data is
the consequence of studies not specifically geared towards
sensitive neurological insult/injury detection and the
significant functional benefits of TAVI in patients who
are ineligible or at high-risk for SAVR. However, the na-
ture of neurological injury becomes of increasing interest
as refinement of TAVI continues with the expectation
that complications can and should be minimised. In-
deed, the greatest barrier to TAVI extending into lower
surgical risk and younger populations remain the risk
of neurological injury.
Objectives
The SANITY study (ACTRN12613000083796) aims to
provide the most comprehensive characterisation to
date of neurological insult and injury - both clinically
apparent and silent – post-TAVI and SAVR. These en-
compass pre-existing patient factors, and both intra- and
post-operative factors thought to influence neurological
insult and injury during aortic valve interventions. It
is hoped that improved understanding of these associ-
ations will permit detailed characterisation of neuro-
logical injury during TAVI compared to the gold-standard
management of SAVR, and allow for the identification
of predictors of such injury and previously unrecognised
neuroprotective strategies.
Specifically, the objectives are:
Primary Objectives: Characterise neurological injury
(MRI evidence of new ischaemic lesions) during the TAVI
procedure compared with SAVR
Secondary Objectives:
1. Define the association between incidence of
neurological insult (intraprocedural monitoring) and
injury with:Severe Aortic Stenosis
High-risk SAVR candidates TAVI candidates
Access Route
Transfemoral Transaortic Transapical
Figure 2 SANITY study design.– Procedure (TAVI, SAVR)
– TAVI access (transfemoral, transapical, transaortic)
2. Define the association between incidence of
neurological insult, radiological evidence of
injury and:
– Clinically apparent neurological injury
– New onset atrial fibrillation
– Neurocognitive dysfunction
– Degree of vascular/aortic valve calcification
– Rapid ventricular pacing and cerebral desaturation
– Serological markers of neurological injury (S100B
and GFAP)
3. Validate GFAP as a serological marker of
neurological injury in cardiovascular interventionHypotheses
Based on the current concept of neurological insult and
extrapolation of procedural risk factors for embolisation,
it is hypothesised that neurological injury is less pro-
nounced with:
1. SAVR than TAVI, due to the removal of the valvular
source of embolisation, which in TAVI persists,
pushed against the wall of the aorta and potentially
acting as a nidus for calcific emboli and altered
rheology, promoting thrombosis.
2. A transapical/transaortic than transfemoral
approach. Transapical/transaortic routes minimise
the risk of disrupting calcific plaques especially in
the aortic arch, an inherent risk with femoral access.
Methods
Study design
This is a prospective, multicentre, non-randomised and ob-
servational study comparing the incidence of neurological
injury associated with TAVI of the Edwards SAPIEN-XT
(Edwards LifeSciences Irvine, CA, USA) under general an-
aesthetic versus bioprosthetic SAVR. Ethics approval has
been obtained from the Human Research Ethics Commit-
tee of the Prince Charles Hospital, Brisbane, Australia
(HREC/12/QPCH/291) and informed consent will be ob-
tained from all participants prior to enrolment.
Regularly held ‘Heart Team’ meetings - comprising of
multiple disciplines including echocardiologists, interven-
tional cardiologists, nurses and cardiothoracic surgeons –
will assess high-risk patients with severe AS. Here, patients
will be allocated to the intervention clinically indicated.
Pending informed consent, such patients will be consecu-
tively recruited into the SANITY study, resulting in cohort
grouping as outlined in Figure 2.
Patient population
Thorough pre-, intra- and post-procedural assessments
allow results to be adjusted for baseline status, thus per-
mitting an inclusive approach to enrolment. As such, only
patients unable to participate in aspects of assessment or
enrolled in other studies (Table 2) will be excluded.
Table 2 Eligibility criteria
Inclusion criteria Exclusion criteria
I. Informed consent for participation I. Lacks capacity to consent for
him or herself
II. Severe aortic stenosis
i. AVA <0.8 cm2 II. Pre-existing neurological
impairment
ii. Mean aortic valve gradient
>40 mmHg
i. Modified rankin score
≥ 3 (i.e. moderate disability;
requiring some help, but able
to walk without assistance)iii. Peak jet velocity >4 m/s
III. Planned TAVI or SAVR
IV. High-surgical-risk III. Contraindication to MRI
(including incompatible metallic
prosthesis/foreign body, inability
to lie flat, claustrophobia
requiring sedation)
i. STS score >8%
ii. Logistic EuroSCORE >20%
iii. Logistic EuroSCORE II >10% IV. Non or poor English-speaking
due to nature of and unknown
validity in such populations
cognitive testing
V. Previous aortic valve repair/
replacement
VI. Coronary artery disease
requiring revascularisation
(including patients undergoing
combined AVR and CABG)
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The complete assessment regime and timing of each
component can be found in Figure 3. Where relevant,
this regime was designed to be consistent with the as-
sessments and endpoints recommended by the Valve
Academic Research Consortium updated standardised
endpoints (VARC-2) [17]. A multi-disciplinary approach
has been adopted to ensure that relevant experts address
each assessment domain.Figure 3 Overview of SANITY assessments.Medical/medication history
Qualified medical or nursing personnel will administer
a detailed, standardised questionnaire, either at the time
of consent or, in cases of telephone consent, at first
subsequent contact. This is aimed at identifying all
pre-existing cerebrovascular and neurocognitive risk
factors and assigning formal surgical-risk scores using
the Society for Thoracic Surgeons Predicted Risk of
Mortality (STS-PROM) scale and European System for
Cardiac Operative Risk Evaluation (EuroSCORE) II.
At each contact specific questioning and chart review
will target transient ischemic events that might other-
wise be missed using the neurological assessment
protocol outlined below.
Neurological and cognitive assessment
There are no standards or recommendations guiding neu-
rocognitive assessment in the TAVI population. Cognitive
function will primarily be assessed with application of
the Montreal Cognitive Assessment (MoCA). This tool
is generally considered more sensitive for vascular cogni-
tive impairment than the mini-mental state examination
(MMSE) due to the inclusion of a thorough executive
function assessment [18]. Additionally, as appropriate, the
Confusion Assessment Method (CAM) or the intensive
care unit (ICU) equivalent – CAM-ICU, will be performed
for the detection of delirium [19]. These tests will be
administered prior to the index procedure and at day 3,
6 weeks and 6 months post-index procedure.
Clinical neurological assessment
The National Institutes of Health Stroke Scale (NIHSS)
is a widely validated tool, which facilitates the standar-
dised objective quantification of impairment caused by
stroke. Categorisation of stroke severity (no stroke,
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stroke and severe stroke) is permitted, based on the
overall score. Where stroke is identified (pre-existing or
new), the modified Rankin Scale (mRS) will be applied
to measure and monitor stroke-related disability. These
assessments will be applied at the same time points as
outlined for the cognitive assessment tools.
Serological assessments
Numerous serological markers of neurological injury
have been utilised previously in acute ischemic stroke
(AIS), however few studies have evaluated their applica-
tion specifically in patients undergoing cardiovascular
interventions; thus, the ideal marker in this setting is un-
known [20]. Following careful consideration of strengths
and weaknesses of each (Additional file 1: Table S1),
GFAP and S100B were selected for use in the SANITY
study. The time points for testing will be pre-procedure
and daily for four days post-procedure.
Imaging assessments
Echocardiography
Echocardiography (either transoesophageal or trans-
thoracic) will be performed on all patients prior to and
following the aortic valve procedure for the purposes of
grading aortic stenosis and valve function. The TAVI
Echocardiographic Calcification Score (TAVI-ECS) will
be applied [21]. Additionally, assessment for intra-
cardiac thrombi and spontaneous echo contrast will be
sought to aid assessment of pre-existing procoagulant
state [22].
Carotid duplex ultrasound
It is feasible that carotid artery stenosis (CAS) may
play a role, albeit currently undefined, in post-
operative stroke [23]. As such, carotid duplex ultra-
sound will be performed on all patients at baseline
to identify CAS within the common, internal and ex-
ternal carotid arteries. Stenosis and plaque burden
will be graded, taking into consideration all informa-
tion from B-mode, pulsed-wave and colour-flow
Doppler.
CT Chest/vascular calcification score
Arterial calcification correlates with atherosclerotic plaque
burden [24]. The Agaston Score Equivalent (ASE) is a
widely used method of measuring the calcified plaque bur-
den in coronary arteries using non contrast CT [25]. Thus,
a low dose, non-contrast acquisition will form part of the
CT angiographic assessment of the aorta and the iliofe-
moral access arteries as routinely performed for TAVI
suitability assessment and planning. These images will be
loaded into Syngo.Via (Siemens Healthcare, Munich,
Germany) and Calcium Score/ ASEs of the aorta will bequantitatively calculated for each of the aortic vessel seg-
ments, including the aortic root and valve leaflets. The
correlation between the vascular and aortic valve plaque
burden and neurological insult can thus be determined.
Magnetic resonance imaging (MRI)
Recognised as the most sensitive technique for the de-
tection of acute ischemic cerebral infarcts, DWI detects
the restriction of water diffusion in cerebral tissue
caused by hypoxic oedema within minutes of ischemia
onset. Increased signal intensity on DWI is reliably De-
tectable 4 hours post-insult and persists for up to 10 days
[26]. Lesions representing brain infarct can be quantified
in number, size, and volume using this modality.
Susceptibility Weighted Imaging (SWI) is a relatively
new MRI sequence which is highly sensitive to the local
magnetic field inhomogeneity caused by paramagnetic
substances including the haem group in haemoglobin. SWI
is commonly used as an adjunct to DWI in the assessment
of cerebral ischemia as it is extremely sensitive for detect-
ing haemorrhagic transformation within regions of infarc-
tion; can demonstrate acute thromboemboli sufficient to
occlude arteries and can detect micro-haemorrhage, sus-
pected to originate from diapedesis of red blood cells
across overtly permeable capillaries. Peak incidence of
haemorrhagic transformation occurs between 48 hours
and 5 days and can persist for years [27].
Patients will undergo a baseline MRI study <48 hours
prior to intervention. This comprehensive study will
include standard fast spin echo sequences, baseline DWI
and SWI sequences and time of flight angiography of the
circle of Willis to document pre-existing disease. At day 4
(±2) post-intervention, and following removal of tempor-
ary pacing wires where applicable, a limited study consist-
ing of DWI, SWI, T2 Flair and T1-weighted imaging will
be performed. This interval length allows for sufficient pa-
tient recovery post-procedure to safely undergo an MRI
examination and allows for establishment of the MRI de-
tectable changes and maximum evolution of the ischemic
change [28]. This limited acquisition is performed in
15 min for increased patient tolerance. A further limited
examination after 6 months will include DWI and SWI,
demonstrating DWI resolution, infarct complications and
finally accounting for all SWI lesions.
Monitoring
Near infrared spectroscopic (NIRS) Cerebral Oximetry
Transcranial cerebral oximetry non-invasively monitors
cerebral oxygen saturation (rSO2) in the frontal lobes of
the brain and has been shown to correlate with cerebral
venous oxygen saturation, which is traditionally considered
the ‘gold-standard’ for determining oxygen delivery/
consumption [29]. Accepted thresholds for cerebral is-
chemia are a rSO2 of <50% or a decline of >20% [30].
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of the SANITY study with use of INVOS™ (Covidien,
Boulder, CO) specifically to monitor the cerebral oxy-
gen delivery compromise associated with the proce-
dure, and in particular with rapid ventricular pacing
[31,32].
Invasive blood pressure
Hemodynamic instability leading to systemic hypotension
may impair cerebral perfusion pressure beyond auto-
regulatory capacity, resulting in hypoperfusion [33]. While
itself a cause of ischemia, low cerebral flow magnifies
the effects of micro-emboli by impairing their clearance
and permitting small emboli to lodge.
Telemetry
Intra-operative telemetry will be employed to measure the
number and duration of rapid ventricular pacing episodes
and to detect intra-operative rhythm abnormalities.
Quality of life
Quality of life (QoL) assessment during post-procedural
follow-up is crucial to determining the clinical benefit of
TAVI and fully appreciating the consequences of neuro-
logical and cognitive insult and injury. Recommenda-
tions of the VARC-2 necessitate both a health-specific

























Figure 4 Overview of SANITY variables and endpoints.careful consideration of each (Additional file 2: Table S2),
the heart failure specific Kansas City Cardiomyopathy
Questionnaire (KCCQ) [35], and the generic European
Quality of Life instrument-5D (EQ-5D) [36] were selected.
These will be performed prior to and 6 months following
index procedure.
Functional outcome measures and frailty
Functional capacity will be measured objectively by the
six-minute walk test (6MWT), conducted according to
American Thoracic Society guidelines [37]. This simple,
practical and inexpensive sub-maximal exercise test as-
sesses functional capacity [38], is closely linked to acti-
vities of daily living and has been proposed as both a
functional status indicator and an outcome measure
[39]. Similarly, gait speed is an important indicator of
frailty [40], with slow gait a strong predictor of adverse
outcomes, including disability, high healthcare utilisation
and mortality [41].
Frailty describes a vulnerability to adverse events that
is associated with, but separate from chronological age
[42]. Implicitly, all patients requiring TAVI as opposed
to open aortic valve surgery must have frailty as a barrier
to standard treatment. Frailty is therefore an important
contributor to the choice of TAVI and a potential con-
founder regarding outcomes, including delirium [43]. The
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ciation of those who are unable to complete performance
based tests - the frailest frail [44].
Endpoint definitions
The endpoints for the SANITY study are outlined in
Figure 4. The primary endpoint focuses on the charac-
terisation and quantification of the neurological injury as
detected by new ischemic lesions on MRI. Secondary
endpoints focus on the clinically apparent neurological
injury sustained and markers of insult/injury.
Statistical analysis
An estimated 100 patients will be recruited into this study,
fifty in each of the two treatment arms (SAVR and TAVI)
and at least 20 patients in each TAVI subgroup (transfe-
moral and transapical/transaortic). Fifty patients per group
provides 90% power to detect differences in the incidence
of new DWI lesions (primary endpoint) with two-sided
statistical significance of 5%, assuming overall incidence
estimates of 76% and 45% with TAVI and SAVR, respec-
tively, as previously reported.
Multiple regression models will be used to adjust for
potential confounders identified based upon clinical im-
portance and statistical selection. The key output will
be the estimated treatment difference and 95% confi-
dence intervals for the primary group from the multiple
regression models. Additionally, longitudinal analysis
will be used to examine all outcomes with repeated
data, again using multiple regression models. Treat-
ment failure and withdrawal will be considered on an
intention-to-treat basis, with the aim of providing a
more realistic estimate of the difference between groups
in clinical practice.
Discussion
The SANITY Study offers the most comprehensive
neurological/neurocognitive assessment of the TAVI and
high-risk SAVR patient population to date. Additionally,
well-established and recommended assessments are
complemented by those that are novel and unique,
thereby offering the potential of improved under-
standing of the interventions in question, correlation
of risk factors and prognostic markers, and validation
of assessment tools themselves. Such knowledge is
vital to establishing both suitable assessment batteries
and guidelines in this unique, high-risk group of pa-
tients, and to advancing strategies for neurological
injury reduction.
Limitations
Across all TAVI literature, the identification of risk-
matched control groups has proven controversial. The va-
lidity of high-risk SAVR patients as a ‘control group’ haspreviously been questioned, given that the level of health
risk is a factor determining suitability for the procedure.
Such difference also exists between access approaches,
with transapical/transaortic typically considered a second
line option where severe vascular disease excludes a trans-
femoral approach. Furthermore, these procedures differ
vastly, most notably in the use of cardiopulmonary bypass,
obscuring the exact cause of any difference identified
between study groups. However, comparison between
these two groups does offer clinical relevance as SAVR
is the current ‘gold-standard’ for eligible patients with
AS and the challenge is in selecting the most appro-
priate procedure in patients who are considered suit-
able for both.
This study will be non-randomised and non-blinded.
Though multiple regression analysis will be used to mi-
nimise confounding, this is not a substitute for blinding
or randomisation, and unmeasured confounders may
produce hidden bias.
Finally, a clinical follow-up duration of 6 months limits
conclusions regarding delayed and late neurological injury.
However, such a timeframe can be justified, given that
DWI findings resolve within this period and reversible
neurocognitive deficits generally resolve by 3 months [12].
Consequently, the financial costs and patient burdens of
prolonging follow-up cannot be ethically justified.
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